Journal of
eISSN: 2376-0060
Submit manuscript...
Editorial Volume 10 Issue 1
Lung cancer patients receiving immune checkpoint inhibitors: safety and immunogenicity of MRNAcovid-19 vaccination
Attapon Cheepsattayakorn,1,2 
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
Ruangrong Cheepsattayakorn,3 Porntep Siriwanarangsun1
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
1Faculty of Medicine, Western University, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Thailand
3Department of Pathology, Faculty of Medicine, Chiang Mai University, Thailand
Correspondence: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road, Changklan Muang Chiang Mai 50100, Thailand
Received: March 01, 2023 | Published: March 8, 2023
Citation: Cheepsattayakorn A, Cheepsattayakorn R, Siriwanarangsun P. Lung cancer patients receiving immune checkpoint inhibitors: safety and immunogenicity of MRNA-covid-19 vaccination. J Lung Pulm Respir Res. 2023;10(1):15-16. DOI: 10.15406/jlprr.2023.10.00294
Editorial
Currently, in cancer or lung-cancer patients, ICIs (immune checkpoint inhibitors), such as anti-CTLA-4, anti-PD-1 (anti-programmed cell death protein 1), anti-PD-L1 (anti-programmed death-ligand 1 antibodies), etc. are widely prescribed as an agent or in other combined treatment modalities.1 Due to immune-associated adverse events (iaAEs), these ICIs can facilitate antitumor effects, such as interstitial pneumonitis, endocrine-gland-disorders-associated abnormal hormone secretion2 that can be caused and aggravated by mRNA-based-COVID-19 vaccines (Figure 1).1,3
Figure 1 Demonstrating patients developing an iaAE (irAE)..
In conclusion, COVID-19 vaccination, particularly, mRNA-COVID-19 vaccination among ICIs-treated-lung-cancer patients should be assessed due to being classified as a vulnerable population.
The lot demonstrates the total observation period (d) from the initiating date of the immune checkpoint inhibitors (ICIs) treatment regimen to the end-observation date. The two-doses-of-mRNA-vaccine-against-SARS-CoV-2 (COVID-19) dates are indicated by triangles, and the date of onset of an iaAE(irAE) is indicated by a dot for each of the 26 patients who developed an iaAE(irAE) before vaccination and the seven patients who developed an iaAE(irAE) after vaccination.1
(iaAE : immune-associated adverse event; ICI : immune checkpoint inhibitor; irAE : immune-related adverse event; mRNA : messenger Ribonucleic Acid; SARS-CoV-2 : severe acute respiratory syndrome coronavirus 2 (COVID-19)).
Acknowledgments
None.
Conflicts of interest
There are no conflicting interests declared by the authors.
Funding
None.
References
- Hibino M, Uryu K, Takeda T, et al. Safety and immunogenicity of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 in patients with lung cancer receiving immune checkpoint inhibitors : a multicenter observational study in Japan. J Thorac Oncol. 2022;17(8):1002–1013.
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–1768.
- Desage AL, Bouleftour W, Rivoirard R, et al. Vaccination and immune checkpoint inhibitors : does vaccination increase the risk of immune-related adverse events ? : a systematic review of literature. Am J Clin Oncol. 2021;44(3):109–113.
©2023 Cheepsattayakorn, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.